Aurinia’s Response to COVID-19
Aurinia is closely monitoring the evolving impacts of the COVID-19 pandemic and we are taking necessary steps to help ensure the safety of our employees and their families, support people living with autoimmune and inflammatory diseases and their care partners, and the communities in which we live and work. We are focused on executing on our regulatory and clinical goals as we work to deliver novel therapies to people living with autoimmune and inflammatory diseases.
As the situation evolves and changes, we are here to answer any questions you may have.
- For people living with lupus nephritis, please visit https://www.allinforlupusnephritis.com, to access trusted resources and timely information.
- For inquiries about clinical trials, please contact email@example.com.
- For investors or media, please visit our investors site https://ir.auriniapharma.com/ or reach out to Glenn Schulman, Senior Vice President, Corporate Communications and Investor Relations at firstname.lastname@example.org.
As the COVID-19 pandemic is rapidly evolving, Aurinia will continue to evaluate any potential business impacts and will provide additional updates, if needed.
Page updated on May 15, 2020